Syndax Pharmaceuticals, Inc. (SNDX) Receives $24.29 Consensus PT from Analysts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has received a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $24.29.
Several research analysts recently commented on SNDX shares. Nomura dropped their target price on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 11th. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Oppenheimer lifted their target price on shares of Syndax Pharmaceuticals to $29.00 and gave the stock an “outperform” rating in a report on Friday, August 11th. Instinet reiterated a “buy” rating and issued a $22.00 target price (down previously from $27.00) on shares of Syndax Pharmaceuticals in a report on Monday, August 14th. Finally, Citigroup set a $20.00 target price on shares of Syndax Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th.
Syndax Pharmaceuticals (SNDX) traded down $0.47 during mid-day trading on Thursday, hitting $8.29. 177,356 shares of the company traded hands, compared to its average volume of 301,243. Syndax Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $15.70.
Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.12. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.30 million. During the same quarter in the previous year, the business earned ($0.84) EPS. Syndax Pharmaceuticals’s quarterly revenue was up .0% compared to the same quarter last year. research analysts forecast that Syndax Pharmaceuticals will post -3.03 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. New York State Common Retirement Fund increased its holdings in shares of Syndax Pharmaceuticals by 421.9% during the 2nd quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after purchasing an additional 7,599 shares during the period. Trexquant Investment LP bought a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $133,000. Airain ltd bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $150,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $154,000. Finally, Bank of Montreal Can bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $158,000. Institutional investors own 61.69% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/12/03/syndax-pharmaceuticals-inc-sndx-receives-24-29-consensus-pt-from-analysts.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.